Inhibition of angiogenesis in the management of refractory gastrointestinal bleeding in patients with LVAD support.

Sara S InglisRabea AslehVivek N IyerSarah D SchettlePhilip J SpencerMauricio A VillavicencioRichard J RodehefferSudhir S KushwahaAtta BehfarAndrew N Rosenbaum

Published in: Artificial organs (2023)

Anti-angiogenic therapy with IV bevacizumab and/or low-dose oral pazopanib appears to provide benefits in patients with LVAD-associated GIB with reduced hospitalizations, blood transfusions, and need for GI endoscopic procedures.

Keyphrases

low dose
left ventricular assist device
ultrasound guided
endothelial cells
high dose
vascular endothelial growth factor
metastatic colorectal cancer
wound healing
mesenchymal stem cells
cell therapy